It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending ...

Women of reproductive age with T2D who have low contraception use take medications that are not recommended for pregnancy.

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk, the maker of Ozempic, said in a statement that it 'remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product ...

A man has been arrested after a suspicious item was found at King’s Cross tube station, forcing thousands of passengers to evacuate. Officers were called to the busy station shortly before 6pm ...

Where that 1950s-set UFO chiller blended “The X-Files,” B movies, and classic radio dramas, “The Rivals of Amziah King” cross-pollinates a bluegrass musical, beekeeping drama, a Native ...

In their first double-digit victory in almost a month, New York’s offense was humming behind a balanced attack. It got rejuvenated performances from Josh Hart, Karl-Anthony Towns, OG Anunoby and ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.

Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...